Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024

March 14, 2024 09:05 AM IST | By Cision
 Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024
Image source: Kalkine Media

DONGGUAN, China, March 14, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, continues its commitment in empowering the Indian IVD industry at Medical Fair India 2024, which is held from March 13 to 15 at Mumbai, India. As one of the most significant medical trade fairs in India, the event provides a crucial platform for Fapon to showcase its innovative IVD technologies and one-stop solutions tailored for IVD manufacturers.

Fapon team in the Medical Fair India 2024
Fapon team in the Medical Fair India 2024

During the event, Fapon is introducing novel and innovative IVD products, technologies and solutions to the Indian market. These offerings include new biomarkers, blockers, bulk reagents, assays and instrument platforms, all aimed at addressing the evolving needs of the local healthcare industry.

Dedicated to supporting local IVD partners, including the industry's leading players, Fapon is leveraging its comprehensive one-stop solutions to facilitate the development of the local IVD industry. These solutions include key raw materials, reliable bulk reagents, open-instrument platforms, customization services, and technical assistance that will collectively enable Indian IVD companies to develop advanced diagnostic tests efficiently and effectively.

With a track record of reliability and collaborative efforts in India, Fapon has become one of the most trusted IVD suppliers in the industry. Its deep industry knowledge and guided insights have facilitated local manufacturers in overcoming complex development challenges as well as accelerating the innovation of IVD products in the local market.

"Fapon is committed to bolstering the growth of the Indian IVD industry," shares Dr. Sandeep K. Vashist, Senior Global IVD Product Director at Fapon Biotech Inc. "We are proud to empower manufacturers with our comprehensive solutions, enabling them to improve the local diagnostic capabilities which will positively impact the quality of patient care in India."

About Fapon

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.

Follow us on LinkedIn (Fapon) or visit our website https://en.faponbiotech.com/ 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.